Matinas BioPharma Holdings (MTNB) Amortizatization of Intangibles (2018 - 2026)
Matinas BioPharma Holdings (MTNB) reported Amortizatization of Intangibles of $74000.0 for Q1 2026, up 7300.0% year-over-year from $1000.0 in Q1 2025, and up 122.77% quarter-over-quarter from -$325000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Amortizatization of Intangibles (2018 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 9 years of Amortizatization of Intangibles data on file, last reported at $74000.0 in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $74000.0, up 7300.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$249000.0 (down 154.37% YoY), and the FY2025 annual result was $4000.0, down 99.34% from the prior year.
- Amortizatization of Intangibles advanced to $74000.0 in Q1 2026 per MTNB's latest filing, from -$325000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $156000.0 in Q4 2024 and troughed at -$325000.0 in Q4 2025.
- A 5-year average of $37882.4 and a median of $44000.0 in 2023 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2024 and 2025: Amortizatization of Intangibles jumped 14800.0% in 2024, then slumped 308.33% in 2025.
- A 5-year view of Amortizatization of Intangibles shows it stood at $129000.0 in 2022, then sank by 163.57% to -$82000.0 in 2023, then surged by 290.24% to $156000.0 in 2024, then sank by 308.33% to -$325000.0 in 2025, then jumped by 122.77% to $74000.0 in 2026.
- Business Quant data shows MTNB's Amortizatization of Intangibles at $74000.0 in Q1 2026, -$325000.0 in Q4 2025, and $1000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | 74,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74,000.00 |
| Mar 31, 2026 | 74,000.00 |
| Dec 31, 2025 | -325,000.00 |
| Dec 31, 2025 | -325,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 156,000.00 |
| Dec 31, 2024 | 156,000.00 |
| Sep 30, 2024 | 152,000.00 |
| Sep 30, 2024 | 152,000.00 |
| Jun 30, 2024 | 149,000.00 |
| Jun 30, 2024 | 149,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | -82,000.00 |
| Dec 31, 2023 | -82,000.00 |